820 related articles for article (PubMed ID: 33140878)
1. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
[TBL] [Abstract][Full Text] [Related]
4. Metabolic dysfunction-associated fatty liver disease in people living with HIV.
Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM
Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241
[TBL] [Abstract][Full Text] [Related]
5. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
6. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population.
Ciardullo S; Perseghin G
Liver Int; 2021 Jun; 41(6):1290-1293. PubMed ID: 33590934
[TBL] [Abstract][Full Text] [Related]
8. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
[TBL] [Abstract][Full Text] [Related]
9. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
[TBL] [Abstract][Full Text] [Related]
10. Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools.
Braude MR; Con D; Lubel J; Bidwai A; Nguyen HT; Sharmamiglani S; Clarke D; Dev A; Sievert W
Hepatol Int; 2021 Jun; 15(3):812-820. PubMed ID: 34081288
[TBL] [Abstract][Full Text] [Related]
11. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV.
Milic J; Menozzi V; Schepis F; Malagoli A; Besutti G; Franconi I; Raimondi A; Carli F; Mussini C; Sebastiani G; Guaraldi G
AIDS; 2020 Nov; 34(13):1915-1921. PubMed ID: 33009010
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter.
Mak LY; Chan AC; Wong TC; Dai WC; She WH; Ma KW; Sin SL; Chu KW; Seto WK; Yuen MF; Lo CM; Fung J
BMC Gastroenterol; 2023 Sep; 23(1):307. PubMed ID: 37700227
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy.
Perazzo H; Cardoso SW; Yanavich C; Nunes EP; Morata M; Gorni N; da Silva PS; Cardoso C; Almeida C; Luz P; Veloso VG; Grinsztejn B
J Int AIDS Soc; 2018 Nov; 21(11):e25201. PubMed ID: 30394678
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus.
Cervo A; Milic J; Mazzola G; Schepis F; Petta S; Krahn T; Lebouche B; Deschenes M; Cascio A; Guaraldi G; Sebastiani G
Clin Infect Dis; 2020 Dec; 71(10):e694-e701. PubMed ID: 32280969
[TBL] [Abstract][Full Text] [Related]
15. Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Hepatol Commun; 2022 Aug; 6(8):2070-2078. PubMed ID: 35470984
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
17. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
[TBL] [Abstract][Full Text] [Related]
18. "Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV".
Cervo A; Sebastiani G; Milic J; Krahn T; Mazzola S; Petta S; Cascio A; Guaraldi G; Mazzola G
HIV Med; 2022 Sep; 23(8):911-921. PubMed ID: 35199429
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
[TBL] [Abstract][Full Text] [Related]
20. Metabolic-Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort.
Han WM; Apornpong T; Chattranukulchai P; Siwamogsatham S; Lwin HMS; Boonrungsirisap J; Wichiansan T; Gatechompol S; Ubolyam S; Kerr SJ; Tangkijvanich P; Avihingsanon A
HIV Med; 2023 Sep; 24(9):1000-1012. PubMed ID: 37165782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]